FLT3 and acute myeloid leukemia: Over the past decades, FMS-like tyrosine kinase receptor-3 (FLT3) mutations have been the subject of intensive research because they are the most common type of genetic alterations observed in AML (20–30% of patients), and are associated with increased relapse and poor survival [2].